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Developmental and lineage plasticity have been observed in numerous malignancies and have been correlated with
tumor progression and drug resistance. However, little is known about the molecular mechanisms that enable such
plasticity to occur. Here,we describe the function of the plant homeodomain finger protein 6 (PHF6) in leukemia and
define its role in regulating chromatin accessibility to lineage-specific transcription factors. We show that loss of
Phf6 in B-cell leukemia results in systematic changes in gene expression via alteration of the chromatin landscape at
the transcriptional start sites of B-cell- and T-cell-specific factors. Additionally, Phf6KO cells show significant down-
regulation of genes involved in the development and function of normal B cells, show up-regulation of genes in-
volved in T-cell signaling, and give rise tomixed-lineage lymphoma in vivo. Engagement of divergent transcriptional
programs results in phenotypic plasticity that leads to altered disease presentation in vivo, tolerance of aberrant
oncogenic signaling, and differential sensitivity to frontline and targeted therapies. These findings suggest that
active maintenance of a precise chromatin landscape is essential for sustaining proper leukemia cell identity and
that loss of a single factor (PHF6) can cause focal changes in chromatin accessibility and nucleosome positioning that
render cells susceptible to lineage transition.
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Lymphopoiesis is a carefully orchestrated process in
which hematopoietic stem cells differentiate into B cells
and T cells through the activation of precise gene expres-
sion programs governed by well-described transcription
factors. During the process of lymphocyte differentiation,
gene expression must be activated, silenced, or main-
tained. In B-cell development, the accessibility of specific
genomic loci for binding of transcription factors (e.g.,
PU.1, E2A, EBF1, and PAX5) is vital for transcriptional
regulation. However, the critical mechanisms regulating
the chromatin landscape and transcription factor access
have yet to be elucidated (Schebesta et al. 2002).
Lymphoid cells are terminally differentiated but still
possess the capacity to transdifferentiate into distinct lin-
eages when subjected to specific genetic perturbations.
For example, loss of Pax5 in mature B cells can produce
functional T cells in immune-deficient mice (Cobaleda
et al. 2007). Similarly, Pax5 deletion in pro-B cells allows
for transdifferentiation into macrophages, granulocytes,
osteoclasts, dendritic cells, and natural killer cells (Nutt
et al. 1999). Overexpression of CEBPα/β can transformma-
ture B andT cells intomacrophages (Xie et al. 2004; Laiosa
et al. 2006). In addition, Ebf1 loss converts pro-B cells into
innate lymphoid cells and T cells (Nechanitzky et al.
2013). Interestingly, these lineage-specific transcription
factors are often found to be altered in B-cell acute lym-
phoblastic leukemia (B-ALL). These findings highlight
the plasticity of leukemia cells and how aberrant lym-
phoid developmental programs can favor leukemogenesis
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(Horcher et al. 2001; Rathert et al. 2015; Somasundaram
and Sigvardsson 2015).
Plant homeodomain finger protein 6 (PHF6) was first
described as the single genemutated in the X-linked intel-
lectual disability called Börjeson-Forssman-Lehmann
syndrome (Lower et al. 2002). Inactivating mutations in
PHF6 were subsequently identified in human leukemia
of the T and myeloid lineages, highlighting its role as a
tumor suppressor gene in these malignancies (Van
Vlierberghe et al. 2010, 2011). Our group recently de-
scribed a tumor-promoting role for Phf6 in a murine
model of BCR–ABL1+ B-ALL (Williams et al. 2006;
Meacham et al. 2015). In this study, we found that hair-
pin-mediated knockdown of Phf6 leads to impaired
growth of B-ALL cells in vivo. Altogether, these observa-
tions suggest that PHF6 can act as a tumor suppressor or
an oncogene in a lineage-dependent manner. However,
the molecular mechanisms underlying PHF6’s function
in hematological malignancies remain entirely unknown
(Fig. 1A).
Figure 1. Phf6 loss decreases the leukemogenic potential of cells in vivo and triggers a change in disease presentation. (A) PHF6 is a
lineage-specific regulator of tumor growth in B-ALL and T-cell acute lymphoblastic leukemia (T-ALL). (B). Kaplan-Meier survival
analysis of mice injected with either 103 (dotted) or 106 (solid) Phf6WT (blue) and Phf6KO (red) B-ALL cells. The number (n) of mice per
genotype analyzed is shown. Statistical analysis (log-rank test, Mantel-Cox) was performed for the different groups in comparison
with mice injected with Phf6WT cells. P-values are shown for the comparisons. (C ) Representative hematoxylin and eosin (H&E) (top)
and immunohistochemistry (bottom) staining of serial sections from lymph nodes (LNs) and lymphoma (mass) of recipient mice injected
with Phf6WT, shPhf6, and Phf6KO cells. mCherry immunochemistry demarcates tumor cells. Bars, 600 µm. (D, top) Size comparison of
representative LNs from Phf6WT (left) and Phf6KO (right) recipient mice. (Bottom) Quantification of combined LN weight of Phf6WT
(blue; n = 5) and Phf6KO (red; n = 5) recipients. (E) Tumor burden in the blood of Phf6WT (blue; n = 7) and Phf6KO (red; n = 8) recipient
mice. mCherry demarcates tumor cells. (F ) Bar graphs showing the percentage of the CD4+ fraction among mCherry+ cells isolated
fromPhf6WT (blue;n = 9) andPhf6KO (red; n = 5) tumors in bonemarrow (left) and LNs (right). Data represent themean ± standard deviation
(SD) in D–F. Statistics were calculated with two-sided Student’s t-test. (∗∗∗) P < 0.001; (∗∗∗∗) P < 0.0001.
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Despite the knowledge obtained through sequencing
studies, only a handful of functions have been described
for PHF6. The protein contains two atypical PHD-like
zinc finger domains, implying the capacity to bind modi-
fied histones similar to canonical PHD domains (Wysocka
et al. 2006). However, PHF6 has only been shown to bind
dsDNA in vitro (Liu et al. 2014). In addition, it has been
shown to interact with transcriptional regulatory factors
such as the nucleosome remodeling and deacetylation
(NuRD) complex, the RNA polymerase II-associated
factor 1 (PAF1) transcription elongation complex, and
the rRNA transcriptional activator UBF (Todd and Pick-
etts 2012; Wang et al. 2013; Zhang et al. 2013). To better
understand the function of PHF6 as a potential chromatin
regulator and examine its lineage-specific roles in hema-
tological malignancies, we decided to thoroughly investi-
gate its role in B-ALL. Here, through integrated genomics
and in vivo studies, we show that PHF6 regulates the chro-
matin landscape of B-ALL cells, where it is responsible for
maintaining a chromatin state that enables a transformed
pre-B-cell identity. PHF6 controls the transcription of tar-
get genes by supporting a chromatin configuration that
permits or blocks the binding of lineage-specific transcrip-
tion factors. Furthermore, we show that the associated
transcriptional and chromatin state changes that occur
in the absence of PHF6 contribute to an emerging mecha-
nism of drug resistance, termed pathway indifference
(Cooley et al. 2015). Loss of PHF6 results in chromatin in-
stability and genomic plasticity, which allows malignant
cells to reprogram transcriptional outputs and tolerate
aberrant lineage signaling.
Results
Loss of Phf6 decreases the leukemogenic potential of
B-ALL cells and results in the development of mixed-
lineage lymphoma in vivo
Recent studies suggest that PHF6 can act as a lineage-spe-
cific regulator of tumor growth. However, the molecular
mechanisms underlying PHF6’s function in hematologi-
cal malignancies remain widely unclear (Fig. 1A). To eval-
uate the effects of complete loss of Phf6 on B-ALL growth,
we engineered isogenic Phf6 knockout (Phf6KO) B-ALL
cells using CRISPR–Cas9 (Supplemental Fig. S1A–D;
Ran et al. 2013; Sánchez-Rivera and Jacks 2015). To max-
imize the chance of functionally inactivating the PHF6
protein, we used a domain-focused targeting strategy
(Shi et al. 2015) by using a single-guide RNA (sgRNA) de-
signed to target the second conserved plant homeodomain
(ePHD2), which has been identified as a mutational hot
spot in T-cell acute lymphoblastic leukemia (T-ALL)
(Van Vlierberghe et al. 2010) and acute myeloid leukemia
(AML) (Van Vlierberghe et al. 2011) (Supplemental Fig.
S1B–D). The Phf6KO cells were characterized extensively
with regard to their in vitro growth properties, showing
no significant differences in their proliferation rates and
cell cycle profiles when compared with their wild-type
counterparts (Supplemental Fig. S1E,F).
To determine the effects of complete loss of Phf6 on
B-ALL growth in vivo, we performed syngeneic trans-
plants into immunocompetent recipient mice (Fig. 1B–
F). Tumor formation in mice injected with 106 Phf6KO
cells was significantly delayed compared withmice trans-
planted with (1) Phf6WT cells, (2) cells expressing an
shRNA targeting Phf6 (shPhf6), and (3) Phf6KO cells res-
cued with the Phf6 cDNA (Fig. 1B; Supplemental Figs.
S1G,H, S2A). When the number of transplanted cells
was reduced 1000-fold, Phf6-deficient cells failed to
develop detectable leukemia in recipient animals. Thus,
complete loss of Phf6 reduces the fitness and leukemia-
initiating capacity of B-ALL cells in vivo.
Notably, mice transplanted with Phf6WT and Phf6KO
cells developed malignancies with pronounced differenc-
es. BCR–ABL1+ B-cell leukemia reproducibly presents
with an enlarged spleen and disseminated disease that
infiltrates the bone marrow (BM) and peripheral blood,
as can be seen upon transplantation with Phf6WT cells
(Williams et al. 2006). However, tumors that developed
from Phf6KO cells pathologically resembled lymphoma,
showing prominent lymphadenopathywithmarked blood
vessels rooting from and to the lymph nodes (LNs), which
completely effaced the normal LN histology in recipient
mice (Fig. 1C,D). These tumors resulted in size and
combined organ weights that were >200% greater than
those of wild-type B-ALL recipients (Fig. 1D). Conversely,
tumor burden in the blood and the spleen size of mice
injected with knockout cells were significantly reduced
relative to those from mice injected with wild-type cells
(Fig. 1E; Supplemental Fig. S2B). These changes were
confirmed in a second isogenic Phf6KO B-ALL cell line
(Supplemental Fig. S3A,B). Moreover, reintroduction of
Phf6 cDNA into Phf6KO B-ALL cells resulted in leukemia
that was indistinguishable in latency from that pro-
duced by Phf6WT B-ALL cells, ruling out off-target effects
(Supplemental Figs. S1G,H, S2A). Altogether, the com-
plete loss of Phf6 in B-ALL results in a drastic alteration
of the natural ontology of the malignancy (changing
from leukemic/disseminated disease to lymphoma) and
a consequential extension in survival of recipient mice.
To further investigate the marked differences in disease
presentation between Phf6KO and Phf6WT cells, we
performed immunophenotypic analyses on tumor cells
isolated from the LNs and BM of recipient mice. As
expected, Phf6WT tumor cells isolated from the BM and
LNs expressed the B-cell markers CD19 and B220 and
lacked IgM (Williams et al. 2006). In contrast, tumor cells
isolated fromPhf6KO B-ALL recipientmice showed amod-
est but significant reduction of CD19 and B220 levels
(Supplemental Fig. S2C–F). Strikingly, these tumor cells
also had high levels of CD4 on the cell surface, indicating
that a significant proportion of Phf6KO B-ALL cells aber-
rantly expressed a surface marker characteristic of the
T-cell lineage (Fig. 1F; Supplemental Fig. S3C; Janeway
et al. 1988; Zhu et al. 2010; Rothenberg et al. 2011). Addi-
tional immunophenotypic profiling demonstrated that
leukemia cells from both genotypes did not express mark-
ers of additional lineages, including surface or intracellu-
lar CD3 (Borst et al. 1987) or the myeloid/dendritic cell
marker CD11b (Supplemental Fig. S4A,B; Bell and Bhan-
doola 2008; Wada et al. 2008). As observed previously,
PHF6 regulates chromatin organization
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loss of Phf6 expression in leukemia cells is detrimental
exclusively in the in vivo setting (Meacham et al. 2015).
In addition, Phf6KO cells cultured in vitro did not express
CD4 (Supplemental Fig. S4C). Importantly, the changes in
disease presentation and aberrant expression of CD4 re-
quire the complete loss of function of Phf6, as they cannot
be recapitulated via potent RNAi-mediated suppression of
Phf6 (Supplemental Figs. S2A, S4D–F; Meacham et al.
2015).
To rule out potential effects associated with single-cell
cloning, we generated a clonal line from the Phf6WT pop-
ulation and performed similar survival and immunophe-
notyping experiments (Supplemental Fig. S4G,H). As
expected, mice transplanted with the Phf6WT clone did
not show a significantly different median survival com-
pared with Phf6WT nonclonal cells. In addition, we did
not observe CD4 overexpression in cells isolated from
the LNs and BMofmice injectedwith thewild-type clone,
mirroring the disease established by Phf6WT nonclonal
cells. Altogether, these results indicate that PHF6 is crit-
ical for growth in vivo as a disseminated disease and sug-
gest a role for PHF6 in maintaining a stable B-cell identity
in B-ALL.
Phf6-deficient B-ALL cells have altered expression of
genes involved in lineage specificity
Intrigued by the underlying phenotypic plasticity ob-
served in Phf6KO B-ALL tumors, we sought to explore
any potential transcriptional changes behind this pheno-
type by performing RNA sequencing (RNA-seq) (Fig. 2;
Supplemental Fig. S5). Pairwise differential expression
analysis between wild-type and knockout transcriptome
profiles showed that Phf6KO cells had a markedly distinct
Figure 2. The absence of Phf6 promotes an
altered gene expression program in B-cell
leukemia. (A) Heat map showing dif-
ferentially expressed genes (fold change
>4, false discovery rate [FDR] <0.05) in pair-
wise comparisons between Phf6WT (left)
and Phf6KO (right) cells as determined by
RNA-seq. Each column represents a repli-
cate sample. The scale corresponds to
row-wise standardized log2-transformed ex-
pression values for each gene. (B) The top
gene ontology (GO) and PANTHER terms
found to be enriched in Phf6KO cells. The
P-value for each term is plotted as −log10-
(P-value). (C ) GSEA plot depicting sig-
nificant (P < 0.001) changes in pre-B
lymphocyte signature genes upon Phf6
deletion, as compared with Phf6WT cells.
(NES) Normalized enrichment score. (D)
Quantitative PCR (qPCR) analysis of
Phf6WT (blue) and Phf6KO (red) cells trans-
duced with empty vector (EV; solid) or a
vector expressing Phf6 cDNA (cDNA; dot-
ted). Relative mRNA levels for B-cell-asso-
ciated genes are shown: Phf6, Cd22, Cd74,
Il4ra, Lyn, Ly86, and Blk. (E) Schematic
representation of ICA used to identify dif-
ferential expression signatures (indepen-
dent components [ICs]) in the integrated
RNA-seq data set comprised of Phf6WT,
shPhf6, and Phf6KO cells. Hinton diagram
representation of ICA-derived signatures.
Columns denote signatures, and rows
denote samples. Colors denote relative
directionality of gene expression ([red] up-
regulation; [green] down-regulation), and
the size of each square represents the mag-
nitude of the contribution of each sample
to the respective IC. Each signature is
two-sided. Vertical boxes denote statisti-
cally significant (P = 0.01, Mann-Whitney
test) independent components. IC2 identi-
fied a Phf6KO-specific gene signature. (F ) GSEA plot depicting (P = 0.08) enrichment in T-cell signal transduction signature upon Phf6 dele-
tion, as compared with Phf6WT cells. (NES) Normalized enrichment score. Data represent the mean ± SD. Statistics for these data were
calculated with two-sided Student’s t-test. (∗∗) P < 0.01; (∗∗∗) P < 0.001; (∗∗∗∗) P < 0.0001; (n.s.) not significant.
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gene expression pattern when compared with Phf6WT
cells (Fig. 2A; Supplemental Fig. S5A; Supplemental Table
2). Differentially expressed genes between Phf6KO and
Phf6WT cells were significantly enriched in pathways in-
volved in cellular and developmental processes of lym-
phocytes (Fig. 2B), suggesting that complete loss of Phf6
in B-ALL cells selectively affects the expression of genes
involved in lymphoid differentiation and function. Gene
set enrichment analysis (GSEA) (Subramanian et al.
2005) of pairwise comparisons revealed that Phf6KO cells
had a significant decrease in the expression of genes asso-
ciatedwith B-cell development and function (Fig. 2C; Sup-
plemental Fig. S5B, top; Supplemental Table 2; Hoffmann
et al. 2002; Mori et al. 2008). Importantly, the expression
of many of the genes that formed the leading-edge cluster
of this B-cell signature (Cd74, IL4ra, Lyn, Ly86, and Blk)
was restored by introduction of the Phf6 cDNA, indicat-
ing that these changes in gene expression are caused by
the absence of Phf6 in the knockout cells and not an off-
target effect (Fig. 2D). Using independent component
analysis (ICA), we identified a statistically significant
gene signature specific to Phf6KO replicate samples (Fig.
2E; Supplemental Table 2). GSEA of the Phf6KO-specific
signature revealed that Phf6KO cells have a notable enrich-
ment of gene sets associated with T-cell signal transduc-
tion and function, including CD4+ T-cell-specific
pathways (Fig. 2F; Supplemental Fig. S5B, bottom; Supple-
mental Table 2; Hahtola et al. 2006; Jeffrey et al. 2006;
Hutcheson et al. 2008; Abbas et al. 2009; Tokoyoda
et al. 2009). These analyses suggest that Phf6KO B-ALL
cells adopt a transcriptional program similar to CD4+ T
cells upon complete loss of Phf6.
To directly compare murine CD4+ T cells and Phf6KO
B-ALL cells, we applied ICA signature analysis to
RNA-seq data from Phf6WT, shPhf6, and Phf6KO B-ALL
cells and murine CD4+-single-positive (SP) T cells (Sup-
plemental Fig. S5C; Miyazaki et al. 2015). This analysis
unveiled a comparable expression profile between Phf6KO
B-ALL cells and CD4+ T cells that was markedly distinct
from shPhf6 and Phf6WT cells (Supplemental Fig. S5C,
D). These results suggest that complete loss of Phf6 in B-
ALL cells promotes a transcriptional program that partial-
ly resembles CD4+ T cells. It should be noted that the
shPhf6 used in our previous study affects in vivo prolifer-
ation of B-ALL cells but is unable to recapitulate the
breadth of transcriptional changes observed upon com-
plete loss of Phf6 (Supplemental Figs. S4D,E, S5A,D;Mea-
cham et al. 2015). Altogether, these findings further
suggest that PHF6 is critical for the maintenance of
B-cell identity through the positive transcriptional regula-
tion of genes important for the B-cell state.
Global genomic binding profiles suggest that PHF6
interacts with chromatin
We next sought to determine whether the marked dif-
ferences in gene expression profiles between knockout
and wild-type cells were due to chromatin regulation by
PHF6. To gain insight into the distribution of PHF6-bound
sites across the B-ALL genome, we performed ChIP-seq
(chromatin immunoprecipitation [ChIP] combined with
high-throughput sequencing) (Lee et al. 2006) with an an-
tibody against PHF6 (Fig. 3A). We found that PHF6 binds
to both gene bodies and proximal promoter/enhancer re-
gions ofmany annotated genes (Fig. 3A; Supplemental Ta-
ble 3). We observed that genes that are differentially
expressed in knockout cells had more than twofold
enrichment of PHF6 binding at their transcriptional
start sites (TSSs) (Supplemental Fig. S6A). In addition,
we found that there is enrichment of PHF6 bindingwithin
the gene body of lowly expressed genes in Phf6WT cells
(Supplemental Fig. S6B). Together, these data suggest
that the genomic location of PHF6 binding might influ-
ence the transcriptional output in B-ALL cells.
Previous studies have proposed that PHF6 has the abil-
ity to bind both DNA and histone proteins (Todd and
Picketts 2012; Liu et al. 2014). Given these contrasting
ideas, we decided to examine both modalities, first asking
whether PHF6 has any DNA sequence-specific binding
properties in B-ALL cells. To do this, we performed motif
enrichment analysis (Bailey and Elkan 1994) of the DNA
sequences surrounding the PHF6-binding peak summits
near promoters of all genes and differentially expressed
genes (Fig. 3B; Supplemental Fig. S6C). We found that no
significant de novo motifs could be identified for PHF6
itself (Fig. 3B, left column). The motifs that passed the
significance threshold bear a resemblance tomotifs bound
by known transcription factors (Fig. 3B, right column).
Similar results were obtained from a motif search of
genome-wide PHF6-binding peaks (Supplemental Fig.
S6C). Since PHF6 lacked any sequence-specific binding
properties, we next investigated whether PHF6 is part
of a transcription factor complex that could potentially
cobind and coregulate gene expression in B-ALL cells.
To do this, we obtained mouse sequences for the ±1-kb
regions adjacent to the TSSs of differentially expres-
sed genes and assessed the enrichment of known motifs
(those with P-value <0.01 that also have a strong PHF6
signal in ChIP-seq) (https://rdrr.io/bioc/PWMEnrich).
Ultimately, 28 motifs (corresponding to 24 unique tran-
scription factors) were identified as binding sites of
putative interacting partners of PHF6 (Supplemental Ta-
ble 3). These motifs were enriched for transcription
factor-binding sites important during hematopoiesis
and lymphopoiesis, including sites bound by PU.1, NF-
kB, EGR1, EBF1, TCF3 (E2A), and TCF12 (HEB) (Supple-
mental Fig. S6D; Supplemental Table 3; Schebesta et al.
2002; Luo et al. 2004; Carlson et al. 2006; Wildt et al.
2007, Wang et al. 2008; Arenzana et al. 2009). Through
endogenous coimmunoprecipitation (co-IP) experiments,
we confirmed that PHF6 interacts with TCF12 and NF-
kB in B-ALL cells (Fig. 3C, top). However, these inter-
actions are mediated in most part via binding to DNA
rather than protein–protein interactions, as demonstrated
by a notable reduction in immunoprecipitated protein
upon addition of the DNA-intercalating agent ethidium
bromide (EtBr) (Fig. 3C, bottom). These results show
that PHF6 is unable to recognize specific DNA-binding
motifs/sequences and therefore is not acting as a canoni-
cal transcription factor in B-ALL cells.
PHF6 regulates chromatin organization
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We then tested whether PHF6 can regulate gene expres-
sion by interacting with histones and subsequently alter-
ing the chromatin state. In fact, we observed that the
PHF6-binding profile is positively correlatedwith gene ex-
pression (Fig. 3D, left). Specifically, at highly expressed
genes, PHF6 binding is enriched at regions flanking the
TSS, similar to H3K27ac signal location (Fig. 3D). Howev-
er, PHF6 signals tend to be more centered at the TSSs
of genes with lower expression (Fig. 3D, left). In addi-
tion, we found that PHF6-binding enrichment is positive-
ly correlated with the presence of activating histone post-
translational modifications, including H3K27ac and
H3K4me3, whereas low correlation is observed with the
repressive mark H3K27me3 (Fig. 3D [right], E). It had
been demonstrated previously that PHF6 can interact
with components of the NuRD complex as well several
histone proteins (H1.2, H2B.1, H2A.Z, and H3.1) (Todd
and Picketts 2012). Therefore, we decided to investigate
whether these interactions also occur in B-ALL cells.
Through endogenous co-IP experiments, we could not
confirm interactions between PHF6 and components of
the NuRD complex—RBBP4, HDAC1, or HDAC2—in
B-ALL cells (data not shown). However, we were able to
confirm a strong interaction between PHF6 and histone
H3 (Fig. 3F, top). Importantly, this interaction is indepen-
dent of the presence of DNA, as treatment of cell lysates
with EtBr did not interfere with it (Fig. 3F, bottom).
Altogether, these results show that PHF6 exerts tran-
scriptional control of target genes via protein–protein in-
teractions with histones. We conclude that the large
transcriptional changes and the associated phenotypic
plasticity observed in vivo are caused by loss of the
PHF6–chromatin interaction that occurs upon genetic
deletion of Phf6 in B-ALL cells.
PHF6 is necessary for the maintenance of chromatin
organization at lineage-specific genes
Given the lineage promiscuity observed upon loss of Phf6
in vivo, we decided to further compare the transcriptional
states of Phf6WT and Phf6KO cells with those of B and T
cells. We used precurated lists of genes whose expression
is unique and distinguishing to CD19+ B cells and CD4+ T
cells (Supplemental Table 2; Painter et al. 2011). As
Figure 3. PHF6 exerts transcriptional reg-
ulation by interacting with histones rather
than binding sequence-specific DNA sites.
(A) Pie chart showing the distribution of
77,749 PHF6-binding sites across genomic
regions in B-ALL cells. (TTS) Transcription
termination site; (UTR) untranslated re-
gion. (B) De novo DNA sequence motifs
identified in PHF6-bound regions at pro-
moters of differentially expressed genes
with their associated P-values. Shown are
sequence logos of de novo position-weight
matrices found by the MEMEmotif discov-
ery tool (left) or those of known transcrip-
tion factors whose motifs are found to be
most similar to the de novomotif discovery
results by Tomtom software (right). (C )
Endogenous coimmunoprecipitation (co-
IP) assay of TCF12, NF-κB, and PHF6 in
the absence (top) or presence (bottom) of
ethidium bromide (EtBr). Input is 7% of
immunoprecipitation lysate. (D, left) Meta-
gene tracks of PHF6 ChIP-seq signal
averaged over all promoter–TSS tracks
grouped by relative expression levels.
(Red) High; (green) genomic; (purple) low.
(Right) Metagene track of H3K27ac ChIP-
seq signal averaged over all promoter–TSS
regions. Shaded regions around average
tracks denote estimates of 95% confidence
interval (CI) of the metagene average sig-
nals based on resampling. (E) Metagene
tracks of PHF6 ChIP-seq signal and correla-
tion with histone marks: H3K27ac (blue),
H3K4me3 (yellow; GSE66234), H3K27me3
(green). Pearson correlation of PHF6 and
histone ChIP-seq signals across 10-kb re-
gions spanning the TSS. Differentially ex-
pressed genes (solid line) and genome-wide genes (dotted line) are shown. (F ) Endogenous co-IP assay of histone H3 and PHF6 in the
absence (top) or presence (bottom) of EtBr. Input is 7% of immunoprecipitation lysate.
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expected, most of the B-cell signature genes are down-reg-
ulated in Phf6KO cells, whereas the T-cell signature genes
showed bidirectional changes (Fig. 4A). Importantly, this
observation is consistent with the mixed-lineage malig-
nancy that arises from syngeneic transplantation of
Phf6KO cells in vivo (Fig. 1F; Supplemental Fig. S2C–F).
Lineage-specific transcriptional programs are often
characterized by differential chromatin accessibility
(Lara-Astiaso et al. 2014). To determine whether the
changes observed in the B and T gene sets are the result
of altered chromatin organization, we performed ATAC-
seq (assay for transposase-accessible chromatin [ATAC]
Figure 4. PHF6 has distinct binding patterns within lineage-specific genes that result in drastic changes in nucleosome occupancy upon
genetic deletion. (A) Heatmaps comparing gene expression of curated CD19+ B-cell (left) andCD4+ T-cell (right) gene sets between Phf6WT
(left) and Phf6KO (right) cells as determined by RNA-seq. Scale corresponds to row-wise standardized log2-transformed expression values
for each gene. Each column represents a replicate sample. (B) Motif enrichment analysis for DNA regions that undergo significant changes
in chromatin accessibility in Phf6KO cells. (Top) DNA motifs with decreased chromatin accessibility upon loss of Phf6. (Bottom) DNA
motifs with increased chromatin accessibility upon loss of Phf6. (C ) Metagene analysis of nucleosome positions (top) and fold enrichment
of PHF6 binding (bottom) plotted for global analysis (left), the CD19+ B-cell gene set (middle), and the CD4+ T-cell gene set (right) assessed
at TSSs ±1-kb genomic regions. (Top) Nucleosome positions are shown for Phf6WT (solid line) and Phf6KO (dotted line) cells, called by the
NucleoATAC algorithm and normalized for batch effects using the chromVAR package. (Bottom) Metagene tracks of PHF6 ChIP-seq sig-
nal averaged over the TSSs ±1 kb in Phf6WT cells. (−1/+1) +1/−1 nucleosomes flanking the TSS; (NFR) nucleosome-free region. Gray bars
indicate major changes in nucleosome positioning that correspond to enriched PHF6 binding. Shaded regions around average tracks
denote estimates of 95% CI of the metagene average signals based on resampling.
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with high-throughput sequencing) (Buenrostro et al. 2013)
on Phf6WT and Phf6KO B-ALL cells (Supplemental Fig.
S7A–F). Phf6 loss results in focal changes in chromatin ac-
cessibility, with∼700 regions in the genome showing stat-
istically significant differences (Supplemental Fig. S7B).
These changes are evenmore pronounced in the promoter
regions of genes associatedwith B andT cells (Supplemen-
tal Fig. S7C,E,F). This analysis also demonstrated that
changes in chromatin accessibility at promoter regions
are predictive of changes in gene expression (Supplemen-
tal Fig. S7D,E). Consistent with our phenotypic data, dif-
ferential chromatin accessibility analysis revealed that
regions that become less accessible upon Phf6 loss are en-
riched for binding motifs of transcription factors required
for B-cell development (Fig. 4B, top; Schebesta et al. 2002;
Dai et al. 2007; Niebuhr et al. 2013) . Conversely, regions
that became more accessible upon Phf6 loss are enriched
for motifs of transcription factors associated with the de-
velopment of T-ALL and AML (Fig. 4B, bottom; Eyquem
et al. 2004; Thoms et al. 2011; Kiaii et al. 2013; Smeets
et al. 2013). Thus, genomic regions important for B and
T lineage genes as well as their regulatory factor-binding
sites undergo significant changes in chromatin accessibil-
ity upon complete loss of Phf6 in B-ALL cells.
We next asked whether nucleosome positions, in addi-
tion to chromatin accessibility, were undergoing signi-
ficant changes dependent on Phf6 status. To determine
nucleosome positioning with high precision and resolu-
tion, we applied the NucleoATAC algorithm to our data
set (Fig. 4C; Schep et al. 2015). Globally, there are few
differences in nucleosome occupancy between Phf6WT
(Fig. 4C, left, solid line) and Phf6KO (Fig. 4C, left, dashed
line) cells. However, drastic changes in nucleosome occu-
pancy are observed in the lineage-specific gene sets.
Focusing on the CD19+ B-cell gene set, we observed an
increase in nucleosome occupancy at the TSS and within
the gene body upon Phf6 loss (Fig. 4C, middle). When
aligned with the promoter–TSS-binding profile of PHF6
in Phf6WT cells, we observed a large overlap between
regions with enriched PHF6 binding and major shifts in
nucleosome occupancy (Fig. 4C, gray bar). This finding
suggests that PHF6 coordinates nucleosome architecture
at B-cell genes in away that is favorable for transcriptional
activity. When PHF6 is lost, nucleosome occupancy is en-
riched and gene expression decreases (Fig. 4A,C, middle).
Focusing on the CD4+ T-cell gene subset, we observed
decreased nucleosome occupancy surrounding the TSS
in Phf6KO cells (Fig. 4C, right, dashed line), with preferen-
tial depletion at the −1 nucleosome (Fig. 4C, right). Our
data are consistent with promoters undergoing increased
chromatin accessibility, where the −1 nucleosome under-
goes more pronounced depletion (Schep et al. 2015). Fur-
thermore, PHF6 binding is enriched at sites that are
undergoing global shifts in nucleosome occupancy (Fig.
4C, right). The chromatin landscape surrounding the
TSSs of genes important for CD4+ T cells demonstrates
fluidity in Phf6KO cells, leading to increased gene expres-
sion in a subset of T-cell genes (Fig. 4A) and presentation
as amixed-lineage lymphoma in vivo (Fig. 1). The shifts in
nucleosome occupancy that we observed upon complete
loss of Phf6 indicate that B-ALL cells are undergoing
lasting and stable transcriptional changes resulting from
alterations of the chromatin architecture, allowing for ge-
nomic (as well as phenotypic) plasticity. Specific genes
undergoing changes in chromatin accessibility at regula-
tory elements include B-cell-specific genes Btg2 and
Cd74 (both of which become less accessible upon Phf6
loss) and T-cell lineage genes Cd4 (distal enhancer) and
Gata3 (which become more accessible upon Phf6 loss)
(Supplemental Fig. S8A,B). Importantly, we confirmed en-
richment of PHF6 binding at these target genes through
ChIP combined with quantitative PCR (ChIP-qPCR) anal-
ysis (Supplemental Fig. S8C,D), suggesting that the ob-
served shifts in chromatin accessibility are dependent on
the presence of PHF6. In conclusion, we show that PHF6
is necessary for the maintenance of a chromatin state
that is instrumental to B-cell identity and that Phf6 loss
leads to the acquisition of a permissive/open state at loci
of alternate lineages, allowing for the engagement of aber-
rant transcriptional programs that direct the resulting
phenotypic plasticity.
Instability in the chromatin landscape allows
for aberrant lineage signaling
Given the genomic plasticity observed in our Phf6KO
B-ALL cells and the changes in chromatin accessibility
detected at regions of T-cell transcription factor-binding
sites upon Phf6 loss, we hypothesized that the genome of
Phf6KO cellsmaynowbe permissive to aberrant oncogenic
signaling emanating from T-cell lineage factors, such as
NOTCH1. Activating mutations in NOTCH1 are well
documented in >60% of cases of T-ALL (Belver and Fer-
rando 2016), where PHF6 is often found to be comutated
withNOTCH1 (Wang et al. 2011; Li et al. 2016). Therefore,
we tested the effects of overexpression of theNOTCH1 in-
tracellular domain (NICD) in Phf6WT and Phf6KO B-ALL
cells. As expected, we observed that NOTCH1 signaling
dramatically inhibits the growth of Phf6WT B-ALL cells
(Fig. 5A; Rothenberg 2014). However, Phf6KO cells were
viable upon NICD overexpression, with growth rates
equivalent to Phf6WT and Phf6KO vector control cell lines
(Fig. 5A). Transplantation of Phf6KO +NICD cells into im-
munocompetent syngeneicmice gives rise to a latent lym-
phoma with extensive thymic infiltration and elevated
levels ofCD4expression characteristic ofT-cellmalignan-
cies (Fig. 5B–D). In conclusion, PHF6 deficiency in B-ALL
cells creates a permissive chromatin state that allows tran-
scription factors from alternate lineages to bind to their
respective genomic loci, which are normally in a closed
conformation in wild-type cells. Enforced expression of
NOTCH1 (T-cell transcription factor) takes advantage
of the chromatin fluidity characteristic of knockout cells,
where Phf6KO tumors are driven more toward a “T-cell-
like” state instead of a mixed-lineage phenotype.
Phenotypic plasticity underlies differential responses
to anti-cancer treatments in vivo
Clinically, patients with B-cell and T-cell leukemia
and lymphoma undergo different treatment strategies.
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BCR–ABL1-driven B-cell leukemia is often treated with
targeted kinase inhibitors, whereas T-cell leukemia and
lymphoma are treated with intensive chemotherapy regi-
mens (Schultz et al. 2009; Litzow and Ferrando 2015). To
further understand the shift from a disseminated leuke-
mia to a mixed-phenotype solid lymphoma that results
from complete loss of Phf6 in B-ALL cells, we examined
the response of these tumors to targeted therapy (ponati-
nib) and frontline chemotherapy (doxorubicin).
Unbiased transcriptome analysis shows decreased
dependency on BCR–ABL1 signaling pathways, the driv-
ing oncogene in this B-ALL model (Fig. 6A; Williams et
al. 2006; Shamroe and Comeau 2013). Consistent with
this, we observed a marked difference in the response to
ponatinib (third-generation BCR–ABL1 inhibitor) be-
tween Phf6WT and Phf6KO tumors in vivo but not in vitro
(Fig. 6B; Supplemental Fig. S9A). Mice transplanted with
Phf6KO cells and treated with ponatinib have a median
survival of 15 d, while their wild-type counterparts sur-
vived >60 d after treatment (Fig. 6B). Thus, the lineage
plasticity that arises in vivo upon Phf6 loss drives a signif-
icantly decreased response to ponatinib. Furthermore, we
examined the response of Phf6WT and Phf6KO tumors to
the chemotherapeutic agent doxorubicin. We found that
mice transplanted with Phf6KO cells are exquisitely sensi-
tive to doxorubicin treatment in vivo, as demonstrated by
an additional 13-d extension in median survival (essen-
tially doubling their life span) when compared with
mice injected with Phf6WT cells (Fig. 6C; Supplemental
Fig. S9B,C). In conclusion, we found that complete loss
of Phf6 in B-ALL cells changes not only the chromatin
landscape of these tumors but also the phenotypic state,
which is reflected in the formation of a different disease
with vastly distinct responses to anti-cancer therapies.
These findings support a possible underlying mechanism
for the examples of lineage plasticity and drug resistance
observed in a variety of malignancies and demonstrate
that modulation of the chromatin landscape through the
loss of regulation by a single factor (such as PHF6) may
play a crucial role in acquired resistance.
Discussion
The transcriptional regulation of lymphocyte develop-
ment via lineage-specific factors is well characterized,
and the perturbation of this process can promote leuke-
mogenesis (Mullighan et al. 2007). However, the dynamic
regulation of chromatin states underlying transcriptional
activity and its contribution to cancer are yet to be eluci-
dated. In this study, we show that PHF6 is a novel chroma-
tin state regulator important for the maintenance of a
chromatin landscape conducive to B-cell identity in B-
ALL. Through integrated genomics (RNA-seq, ChIP-seq,
and ATAC-seq) and in vivo studies, we demonstrate the
crucial role that PHF6-mediated chromatin modulation
plays in genomic plasticity, cell identity, leukemogenesis,
and response to therapy. Our data convincingly show that
Phf6 loss leads to a chromatin environment that tolerates
aberrant lineage and oncogenic signaling. Moreover,
we demonstrate how malignant cells can hijack chro-
matin instability to reprogram transcriptional output
and cell identity. These findings propose the first mecha-
nistic insights into PHF6’s role in a lymphoidmalignancy.
We show that PHF6 binds to nucleosomes at specific
genomic loci and orchestrates distinct transcriptional pro-
grams. It stabilizes chromatin accessibility at B-cell-
specific genes, while T-cell transcription factor-binding
sites are concealed in compacted chromatin (Fig. 7A).
Upon loss of this single factor, chromatin architecture
Figure 5. Chromatin instability allows for
aberrant T-cell transcription factor signal-
ing. (A) Cell proliferation assay comparing
Phf6WT (blue; up arrow), Phf6KO (red; up
arrow), Phf6WT + control vector (blue; cir-
cle-dotted), Phf6KO + control vector (red;
circle-dotted), Phf6WT +NICD cDNA
(blue; down triangle), and Phf6KO +NICD
cDNA (red; down triangle) cells. n = 3. (B)
Kaplan-Meier survival analysis of mice in-
jected with 106 B-ALL cells of the indicated
genotypes infected with control vector or
activated NICD vector. The number (n) of
mice per genotype analyzed is shown.
Statistical analysis (log-rank test, Mantel-
Cox) was performed for the different groups
in comparison with mice injected with
Phf6WT + control vector cells. P-values are
shown for the comparisons. (C ) Quanti-
fication of the combined thymus weight
of Phf6WT + control vector (blue; n = 4),
Phf6KO + control vector (red unfilled; n = 6), andPhf6KO +NICDcDNA (red patterned;n = 7) recipients. (D) Bar graphs showing the percent-
age of the CD4+ fraction amongmCherry+ cells isolated from Phf6WT + control vector (blue; n = 5), Phf6KO + control vector (red unfilled; n
= 4), and Phf6KO +NICD cDNA vector (red patterned; n = 6) tumors from LNs. Data represent the mean ± SD in C and D. Statistics were
calculated with two-sided Student’s t-test. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗∗) P < 0.0001.
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around B-cell- and T-cell-specific genes undergoes dra-
matic remodeling, resulting in focal genomic plasticity
and acquisition of T-cell lineage markers in B-ALL cells
(Fig. 7B). Given that PHF6 is frequently inactivated in T-
ALL (∼30%) (Van Vlierberghe et al. 2010), we speculate
thatT-cellmalignancies benefit from the permissive chro-
matin landscape that results upon PHF6 loss. Our data
further support the possibility that a significant portion
of T-ALLs (∼30%) (Van Vlierberghe et al. 2010) may
have once started as a B-cell progenitor/precursor that
acquired a mutation in PHF6 during early stages of leuke-
mogenesis and consequently forced the cell of origin into
a “pseudo-T-cell state” that then presented as a T-cell
malignancy.
Lineage switching is a rapidly emerging mechanism of
resistance to targeted therapies. A variety of cancers (in-
cluding lung cancer, prostate cancer, and B-cell leukemia)
can acquire resistance to therapy by relapsing as a histo-
logically distinct malignancy (Sequist et al. 2011; Yu
et al. 2013; Oser et al. 2015; Gardner et al. 2016; Jacoby
et al. 2016; Ku et al. 2017; Mu et al. 2017). The first func-
tional studies investigating this process as a driver of drug
resistance in prostate cancer identified epigenetic repro-
gramming proteins (SOX2 and EZH2) as key effectors of
this phenomenon (Ku et al. 2017; Mu et al. 2017). In our
study, we further demonstrate that active maintenance
of chromatin architecture (by PHF6, a novel chromatin
regulator) is also critical in the response to targeted thera-
py in B-cell leukemia. We postulate that the chromatin
landscape is a pivotal component in the response of
many cancer types to targeted treatments.
Herewe identifed the function of PHF6 in B-ALL and as-
cribed its role in regulating chromatin accessibility to lin-
eage-specific transcription factors. We showed that loss of
Phf6 results in disruption of lineage differentiation via
gross changes in chromatin accessibility, engagement of
alternative transcriptional programs, altered disease pre-
sentation in vivo, and tolerance of aberrant oncogenic
signaling. We established that the proper chromatin land-
scape is essential for maintaining cell identity and that
loss of Phf6 can cause changes in chromatin accessibility
and nucleosome positioning that result in lineage pro-
miscuity. These findings highlight a mechanism of gene
expression maintenance via chromatin landscape modu-
lation that underlies the developmental plasticity charac-
teristic of hematopoietic malignancies.
Materials and methods
Plasmids and cloning
A mouse Phf6 sgRNA (5′-GTACTTCAGGAGATTAAGCG-3′)
was cloned into pX458 vector [pSpCas9(BB)-2A-GFP; Addgen,
48138] (Ran et al. 2013). This sgRNA was designed using the
Broad Institute sgRNA Designer (Doench et al. 2014). A mouse
Phf6 cDNA was obtained from OriGene (MC203493) and subcl-
oned into pMSCV-PGK-GFP. The following NOTCH1-ICD over-
expression vectors were obtained from Addgene: pLPCX-NICD
(Addgene, 44471) and pLPCX-IRES-GFP (Addgene, 65436). The
Figure 6. Loss of Phf6 results in decreased dependence on the driving oncogene BCR–ABL1 in vivo. (A) GSEA plots depicting significant
changes in the targets of the BCR–ABL1 fusion signature (P = 0.0129) and dasatinib resistance signature (P = 0.0056) upon Phf6 deletion, as
compared with Phf6WT cells. (NES) Normalized enrichment score. (B) Kaplan-Meier survival analysis of mice injected with 106 B-ALL
cells of the indicated genotypes with subsequent mock or ponatinib treatment (30 mg/kg daily for four consecutive days). The number
(n) of mice per genotype analyzed is shown. Statistical analysis (log-rank test, Mantel-Cox) was performed for the different groups in
the indicated comparisons. P-value is shown for the comparison. (C ) Kaplan-Meier survival analysis of mice injected with 106 B-ALL cells
of the indicated genotypes with mock or 10 mg/kg doxorubicin (single immunoprecipitation dose) treatment. The number (n) of mice per
genotype analyzed is shown. Statistical analysis (log-rank test, Mantel-Cox) was performed for the different groups in the indicated com-
parisons. P-value is shown for the comparison.
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Phf6 shRNA (5′-GCAAGGGATTTACATGGTTTA-3′) was
cloned into the mir30 backbone (Supplemental Table 1; Dickins
et al. 2005; Meacham et al. 2015).
Antibodies
The antibodies used for Western blotting were anti-HSP90 (BD
Biosciences, 610419), anti-PHF6 N terminus (Bethyl Laborato-
ries, A301-450A), anti-PHF6 C terminus (Bethyl Laboratories,
A301-452A), anti-Histone H3 (C-16) (Santa Cruz Biotechnology,
sc-8654), and anti-PHF6 (Novus, 68262). Secondary antibodies
were anti-rabbit IgG, HRP-linked (Cell Signaling Technology,
7074); anti-mouse IgG, HRP-linked (Cell Signaling Technology,
7076); and anti-goat IgG, HRP-linked (Santa Cruz Biotechnology,
sc-2350). Antibodies used for immunoprecipitation were anti-
PHF6 (Novus, 68262), anti-TCF12 (Cell Signaling Technology,
11825), anti-NF-kB (p65) (Santa Cruz Biotechnology, sc-372),
anti-Histone H3 (Bethyl Laboratories, A300-823A), and normal
rabbit IgG (Santa Cruz Biotechnology, sc-2027). Antibodies used
for flow cytometry were APC anti-mouse B220 (clone RA3-6B2;
BD Biosciences, 553092), V450 anti-mouse IgM (clone R6-60.2;
BD Biosciences, 560575), FITC anti-mouseCD19 (clone eBio1D3;
eBiosciences, 11-0193-81), APC anti-CD4 (clone RM4-5; BD Bio-
sciences, 553051), V450 anti-CD4 (clone RM4-5; BD Biosciences,
560468), FITC anti-CD3 (clone 17A2; eBiosciences, 11-0032), and
APC anti-CD11b (clone M1/70; Biolegend, 101212). Isotype con-
trols used for flow cytometry were V450 anti-IgG2a, κ (clone R35-
95; BD Biosciences, 560377); FITC anti-IgG2b, κ (clone eB149/
10H5; eBiosciences, 11-4031-82); APC anti-IgG2a, κ (clone R35-
95; BD Biosciences, 553932); FITC anti-IgG2a, κ (clone eBR2a;
eBiosciences, 11-4321); and APC anti-IgG2b, κ (clone RTK4530;
Biolegend, 400612). The antibody used for immunohistochemis-
try staining was anti-RFP (Rockland, 600-401-379). The anti-
bodies used for ChIP experiments were anti-PHF6 (Bethyl
Laboratories, A301-451A), anti-H3K27ac (Abcam, ab4729), anti-
H3K27me3 (Abcam, ab6002), anti-PHF6 (Novus, 68262), and nor-
mal rabbit IgG (Santa Cruz Biotechnology, sc-2027).
Cell culture
Murine BCR–ABL1+; p19−/−; mCherry+ B-ALL cells (Williams
et al. 2006) were cultured in RPMI-1640 (Corning) supplemented
with 10% FBS, 4 mM L-glutamine, 50 µM 2-mercaptoethanol,
100 U/mL penicillin, and 100 µg/mL streptomycin. Retroviral
particles were generated and packaged using the Phoenix cell sys-
tem (G.Nolan, StanfordUniversity). Briefly, a calcium phosphate
transfection of 10 µg of plasmid DNA and 5 µg of helper plasmid
(pCMV-Gag-Pol) was used. Transduction efficiencies were as-
sessed 48 h after infection by flow cytometry. To generate Phf6KO
cells, sgPhf6-pX458 plasmid was transfected (Lipofectamine
3000, Life Technologies) into B-ALL cells. Transfected cells
were single-cell-sorted into 96-well plates based on GFP expres-
sion. Cell proliferation assay was performed by plating B-ALL
cells in triplicate (1 million cells per well in 3 mL of medium in
a six-well plate), counting every 24 h by Trypan blue exclusion,
and replating the initial density. This was performed for 7 d.
Drug response analysis
Cells (10,000 per well) were plated in 96-well plates, and medium
containing ponatinib (LC Laboratories, AP24534) or doxorubicin
(Sigma-Aldrich, D1515) was added to achieve the indicated final
concentrations. Cell viability was assessed 48 h after treatment
by propidium iodide (Sigma-Aldrich, 81845) exclusion and flow
cytometry. Inhibitor dilutions were made in cell medium imme-
diately before use. The relative viability compared with controls
diluted in equivalent medium+DMSO is shown.
Western blotting
Cells were lysed with RIPA buffer (Boston BioProducts, BP-115)
supplemented with 1× protease inhibitor solution (Complete
EDTA-free, Roche, 11873580001). Protein concentration of cell
lysates was determined by Pierce BCA protein assay (Thermo-
Fisher Scientific, 23225). Fifty micrograms to 70 µg of total pro-
tein was separated on 4%–12% Bis-Tris gradient SDS-PAGE
gels (Life Technologies) and then transferred to PVDFmembranes
(EMD Millipore, IPVH00010) for blotting.
Co-IP
Antibodies were precleaned before attaching to magnetic beads
using the Pierce antibody cleanup kit (ThermoFisher Scientific,
44600). A total of 10 µg of antibody was covalently attached to
magnetic beads (ThermoFisher Scientific, 88828) and incubated
with 1 mg of protein for 2 h at room temperature while rotating
(or overnight at 4°C). Immunoprecipitation was performed ac-
cording to the manufacturer’s directions (Pierce Direct magnetic
immunoprecipitation/co-IP kit, Thermo Fisher Scientific). For
DNA-dependent interactions, 50 µg/mL EtBr was added, and ly-
sates were incubated for 30min on ice. Samples were centrifuged,
and the supernatant was used for immunoprecipitations.
qPCR
RNA from 2 × 106 B-ALL cells was prepared using RNeasy mini-
kit (Qiagen). Synthesis of cDNAwas performed usingM-MLV re-
verse transcriptase (Life Technologies, 28025) with oligo(dT)20
primer. qPCR was done in an Applied Biosystems StepOnePlus
Figure 7. Model of PHF6 as a chromatin state regula-
tor, permitting transcription factor binding through
chromatin accessibility. (A) In wild-type cells, PHF6
binds to the ±1 nucleosome flanking the open TSSs
of genes, allowing B-cell-specific transcription factors
to bind, drive gene expression, and maintain B-cell
identity. Conversely, PHF6 binds nucleosomes sur-
rounding the TSSs of T-cell-specific genes, coordinat-
ing chromatin compaction and thus blocking the
binding of T-cell-specific transcription factors. (B) In
the absence of PHF6, chromatin is no longer main-
tained in an open state, B-cell transcription factors
cannot bind, and expression of B-cell identity genes
is down-regulated. However, T-cell identity genes are no longer inaccessible, allowing T-cell-specific transcription factors to bind and ac-
tivate aberrant transcriptional programs.
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machine with TaqMan fast universal PCR master mix (Life
Technologies, 4352042). Data were analyzed using the com-
parative ΔCT method and normalized to the levels of Gapdh.
The TaqMan gene expression assays (Life Technologies)
used were Phf6 (Mm00804415_m1), Blk (Mm00432077_m1),
Cd74 (Mm00658576_m1), IL4ra (Mm01275139_m1), Ly86
(Mm00440240_m1), Lyn (Mm01217488_m1), Gapdh
(Mm99999915_g1), and Cd22 (Mm00515432_m1).
Genomic DNA isolation and sequencing
GenomicDNA fromB-ALL cells was isolated using the blood and
cell culture DNA minikit (Qiagen) following the manufacturer’s
guidelines. PCR products for sequencing were amplified using
HerculaseII Fusion DNA polymerase (Agilent) (see Supplemental
Table 1 for primers used), gel-purified, cloned into pCR4-TOPO
TA vector (Life Technologies), and subsequently sequenced.
Animal experiments
All animal studies described in this study were approved by the
Massachusetts Institute of Technology Institutional Animal
Care and Use Committee. For syngeneic transplants, 103 or 106
murine BCR–ABL1+p19−/− B-ALL cells (Williams et al. 2006)
were injected via tail vein into syngeneic C57BL/6J (The Jackson
Laboratory, 000664) recipient mice at the age of 6–8 wk. Treat-
ment with 30 mg/kg ponatinib (administered via oral gavage,
treated once daily for four consecutive days), 10 mg/kg doxorubi-
cin (administered via immunoprecipitation, treated once; Nova-
Plus), or vehicle (25 mM citric acid buffer) was initiated upon
significant disease presentation. Mice were observed daily and
sacrificed when moribund (dehydration, ruffled fur, respiratory
distress, and poor motility). Survival curves were generated using
GraphPad Prism version 6.0 software, and the Mantel-Cox test
was applied to pairwise comparisons of survival data. No statisti-
calmethodswere used to predetermine sample size. Investigators
were not blinded to group allocation during experiments and out-
come assessment. Randomization was not used because all ani-
mals used in this study were of similar sex, age, and strain
background.
Organ processing and cell preparation for flow cytometry
When mice reached morbidity, they were sacrificed, and lym-
phoid organs were collected. Briefly, cells derived from the BM
were obtained by flushing the femora and tibiae with B-ALL me-
dium. LNs, spleens, and thymi were isolated; weighed for mass
measurements; ground; and filtered to obtain single-cell suspen-
sion. Subsequently, red blood cells were lysed with ACK lysing
buffer (Life Technologies, A10492-01).
Immunostaining
For cell surface immunophenotyping, leukemia cell suspensions
(cultured and isolated frommice) were collected and treated with
the indicated antibodies. Briefly, 1 × 106 to 2 × 106 cells in 100 µL
of 10% FBS in PBS were incubated with antibody for 1 h at room
temperature in the dark. Antibodieswere used at a 1:100 dilution.
Stained samples were analyzed by flow cytometry.
For intracellular immunophenotyping, leukemia cell suspen-
sions (cultured and isolated frommice)were collected, resuspend-
ed in PBS, and fixed with 4% formaldehyde (Tousimis, 1008A)
solution for 10 min at 37°C. Cells were permeabilized with ice-
cold methanol for 30 min on ice.
Cell cycle analysis
FITC BrdU flow kit (BD Biosciences, 559619) was used for cell cy-
cle analysis. Briefly, 1 × 106 B-ALL cells plated in triplicate were
labeled with 10 µM BrdU for 30 min. Cells were subsequently
fixed and stained with anti-BrdU and 7-AAD and analyzed by
flow cytometry (LSRFortessa, BD Biosciences).
Flow cytometry
FACSAria (BD Biosciences) was used for fluorescence-activated
cell sorting, and LSRFortessa (BD Biosciences) was used for flow
cytometry analysis. Data were analyzed with FlowJo software
(TreeStar version 10).
Histology and immunohistochemistry
For histological and immunohistochemistry analyses, mice were
euthanized by carbon dioxide asphyxiation. Lymphoid tissues
were harvested, fixed overnightwith 10%neutral buffered forma-
lin (VWR), transferred to 70% ethanol solution, and subsequently
embedded in parafilm. Sections were cut at a thickness of 10 µm
and stained with hematoxylin and eosin (H&E) for pathological
assessment. Immunohistochemistry was performed on a Thermo
Autostainer 360 machine. Slides were antigen-retrieved using
Thermo citrate buffer (pH 6.0) in the pretreatment module. Sec-
tions were treated with Biocare rodent block, primary antibody,
and anti-rabbit HRP-polymer (Vector Laboratories). The slides
were developed with Thermo Ultra DAB and counterstained
with hematoxylin in a Thermo Gemini stainer, and coverslips
were added using the Thermo Consul coverslipper.
RNA-seq library preparation
cDNA for RNA-seq libraries was prepared using TruSeq mRNA
library preparation kit (Illumina). Illumina libraries were pro-
duced using SPRIworks (Beckman-Coulter Genomics) with a
200- to 400-base-pair (bp) size selection and enriched with 14 cy-
cles of PCR. Library quality was determined by qPCR and on the
fragment analyzer (Advanced Analytical) and loaded onto two
lanes of 40-nucleotide (nt) single-end sequencing on a HiSeq2000
system (Illumina).
RNA-seq data analysis
Illumina HiSeq2000 40-nt single-end reads were mapped to the
University of California at Santa Cruz (UCSC) mm9 mouse
genome build (http://genome.ucsc.edu) using RSEM (Li and Dew-
ey 2011). Raw estimated expression counts were upper-quartile-
normalized to a count of 1000 (Bullard et al. 2010). Given the
complexity of the data set in terms of a mixture of different con-
ditions, a high-resolution signature discovery approach was used
to characterize global gene expression profiles. ICA, an unsuper-
vised blind source separation technique, was used on this discrete
count-based expression data set to elucidate statistically indepen-
dent and biologically relevant signatures. ICA is a signal process-
ing and multivariate data analysis technique in the category of
unsupervised matrix factorization methods. Conceptually, ICA
decomposes the overall expression data set into independent sig-
nals (gene expression patterns) that represent distinct signatures.
High-ranking positively and negatively correlated genes in each
signature represent gene sets that drive the corresponding expres-
sion pattern (in either direction). Signatureswere visualized using
the sample to signature correspondence schematic afforded by
Hinton plots, where colors represent directionality of gene ex-
pression (red indicates up-regulated, and green indicates down-
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regulated), and the size of each rectangle quantifies the strength of
a signature (column) in a given sample (row). Each signature is
two-sided, allowing for identification of up-regulated and down-
regulated genes for each signature within each sample. Using in-
put data consisting of a gene–sample matrix, ICA uses higher-or-
der moments to characterize the data set as a linear combination
of statistically independent latent variables. These latent vari-
ables represent independent components based on maximizing
non-Gaussianity and can be interpreted as independent source
signals that have been mixed together to form the data set under
consideration. Each component includes a weight assignment to
each gene that quantifies its contribution to that component. Ad-
ditionally, ICA derives a mixing matrix that describes the contri-
bution of each sample toward the signal embodied in each
component. This mixing matrix can be used to select signatures
among components with distinct gene expression profiles across
the set of samples. The R implementation of the core JADE
(Joint Approximate Diagonalization of Eigenmatrices) algorithm
(Rutledge and Bouveresse 2013; https://cran.r-project.org/
web/packages/JADE/index.htm; https://www.bioconductor.org/
packages/release/bioc/html/MineICA.html) was used along
with custom R utilities. The P-value for the knockout-specific
(IC2) signature was P = 0.0119 (Mann-Whitney U-test directional
P-value). Targeted pairwise differential expression analyses were
conducted using EBSeq version 1.4.0 (Leng et al. 2013). Differen-
tially expressed genes from the pairwise comparison between
Phf6KO and Phf6WT B-ALL cells were determined using a signifi-
cance level of false discovery rate (FDR) 0.05 and fold change >1.5.
All RNA-seq analyses were conducted in the R statistical pro-
gramming language (http://www.r-project.org). GSEAwas carried
out using the prerankedmodewith default settings (Subramanian
et al. 2005). Heat maps were generated using the Heatplus pack-
age in R. Integrated RNA-seq signature analysis of B-ALL cells
and a data set from CD4+ SP cells (Gene Expression Omnibus
[GEO] accession code GSE64779, samples GSM1580493–
GSM1580497) (Edgar et al. 2002; Barrett et al. 2012; Miyazaki
et al. 2015) was performed using ICA. All gene lists, signatures,
and sets used in this study are in Supplemental Table S2. A
two-dimensional expression principal component (principal
component analysis [PCA]) plot for each group of cells was gener-
ated by plotting the first two principal components of expression
(explaining 75% and 11% of expression variance, respectively).
Gene ontology (GO) analysis was done using DAVID, and top
GO and PANTHER terms were plotted against their correspond-
ing P-values (log-scale).
ChIP-seq
ChIP was performed as described before (Lee et al. 2006) with a
few adaptations. A total of 150 × 106 cells, grown to a density of
1 × 106 cells per milliliter, was cross-linked for 10 min at room
temperature by the addition of one-tenth of the volume of 11%
formaldehyde solution (11% formaldehyde, 50 mM HEPES at
pH 7.3, 100 mM NaCl, 1 mM EDTA at pH 8.0, 0.5 mM EGTA
at pH 8.0) to the growth medium followed by 5 min of quenching
with 125 mM glycine. Cells were washed twice with PBS, the su-
pernatantwas aspirated, and the cell pelletwas flash-frozen in liq-
uid nitrogen. Frozen cross-linked cells were stored at−80°C.One-
hundred microliters of Protein G Dynabeads (Life Technologies)
was blocked with 0.5% (w/v) BSA in PBS. Magnetic beads were
bound with 10 µg of anti-H3K27ac (Abcam, ab4729), anti-
H3K27me3 (Abcam, ab6002), and anti-PHF6 (Bethyl Laborato-
ries, A301-451A). Nuclei were isolated as described previously
(Lee et al. 2006) and sonicated in lysis buffer (20 mM Tris-HCl
at pH 8.0, 150 mM NaCl, 2 mM EDTA at pH 8.0, 0.1% SDS,
1% Triton X-100) on a Misonix 3000 sonicator for 10 cycles of
30 sec each on ice (18–21 W) with 60 sec on ice between cycles.
Sonicated lysates were cleared once by centrifugation and incu-
bated overnight at 4°Cwithmagnetic beads boundwith antibody
to enrich for DNA fragments bound by the indicated factor. Beads
were washed with wash buffer A (50 mMHEPES-KOH at pH 7.9,
140 mM NaCl, 1 mM EDTA at pH 8.0, 0.1% sodium deoxycho-
late, 1% Triton X-100, 0.1% SDS), buffer B (50 mM HEPES-
KOH at pH 7.9, 500 mM NaCl, 1 mM EDTA at pH 8.0, 0.1%
sodium deoxycholate, 1% Triton X-100, 0.1% SDS), buffer C
(20 mM Tris-HCl at pH 8.0, 250 mM LiCl, 1 mM EDTA at pH
8.0, 0.5% sodium deoxycholate, 0.5% IGEPAL CA-630, 0.1%
SDS), and buffer D (TE with 50 mM NaCl) sequentially. DNA
was eluted in elution buffer (50 mM Tris-HCl at pH 8.0, 10 mM
EDTA, 1% SDS). Cross-links were reversed overnight. RNA and
protein were digested using RNase A and Proteinase K, respec-
tively, and DNAwas purified with phenol-chloroform extraction
and ethanol precipitation. Purified ChIP DNA was used to pre-
pare Illumina multiplexed sequencing libraries. Libraries were
prepared following the TruSeq DNA sample preparation kit ver-
sion 2 (Illumina). Amplified libraries were size-selected using a
2% gel cassette in the Pippin preparation system (Sage Science)
set to capture fragments between 200 and 400 bp. Libraries
were quantified by qPCR using the Illumina library quantifica-
tion kit (KAPA Biosystems) according to the manufacturer’s
guidelines. Libraries were sequenced on the Illumina HiSeq2500
for 40 nt in single-read mode.
ChIP-seq data analysis
To compare RNA-seq with ChIP-seq data sets, normalized RNA-
seq tag counts for each genewere used to plot a heatmap showing
the expression levels of these genes ordered by fold change values.
Among these genes, 1127 symbols were mappable to ENSEMBL
mouse gene IDs (unmappable gene symbols correspondedmostly
to those that are not well characterized) and were used for map-
ping to genomic coordinates. Sequencing reads were mapped to
the UCSC mm9 mouse genome using Bowtie2 (Langmead et al.
2009; Langmead and Salzberg 2012) with at most one mismatch
allowed in seed alignments. Unmapped reads were removed,
and alignments were output in BAM files for peak calling with
the MACS software (Zhang et al. 2008). PHF6 and histone modi-
fication peaks were called using a P-value threshold of 1 × 10−6.
The fraction of reads falling within the called peaks (FRiP) for
PHF6 ChIP-seq data was 25.9% (8,333,082 out of 32,143,465
uniquely mappable reads), showing high ChIP quality. To exam-
ine whether PHF6-binding strength correlates with gene expres-
sion levels, RNA-seq data from Phf6WT cells were sorted and
grouped by expression into three bins corresponding to high, me-
dium, and low expression by separating into three equally sized
bins. Average log2 fold change values over input signals were plot-
ted as ametagene track for each gene set. Plots forH3K27ac signal
enrichment were also generated to confirm promoter activity for
each gene set. To determine PHF6 binding at promoter/enhancer
regions of the differentially expressed genes, genomic sequences
were obtained for the ±5-kb region surrounding the TSSs for these
genes from theUCSCmm9genome assembly and binned into 50-
bp bins. ChIP-seq RPM (reads per million) values for PHF6,
H3K27ac, H3K27me3, and H3K4me3 (publicly available ChIP-
seq data sets were obtained as Sequence Read Archive-lite
files, GEO accession code GSE66234, data sets GSM1617788–
GSM1617789) (Edgar et al. 2002; Barrett et al. 2012; Wang et al.
2015) at these promoter bins were divided by the corresponding
ChIP input (control) reads with a pseudocount of one and then
log2-transformed to show fold enrichment. To show correlation
between PHF6 and histone modification signals, Pearson’s corre-
lation coefficients between corresponding pairs of columns in the
PHF6 regulates chromatin organization
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heat maps were calculated. The MEME suite (Bailey and Elkan
1994) was used for de novo motif discovery of sequences sur-
rounding PHF6-binding peak summits. A 100-nt window up-
stream of and downstream from the peak summits was set to
obtain sequences from the UCSC mm9 genome assembly.
Among all 77,749 PHF6 summits called by the MACS pipeline
(Zhang et al. 2008), 6037 fell within the proximal regulatory re-
gions (±5 kb surrounding the TSS) of differentially expressed
genes, covering a total of 1104 (out of 1123) unique promoters.
For each promoter region, the PHF6 summit was selected with
the highest average peak signal for motif analysis, resulting in
1044 unique summits and their surrounding sequences as input
for the MEME motif discovery tool (Bailey and Elkan 1994). To
see whether PHF6 displays any bias in sequence specificity at
the differentially expressed gene promoters, the top 1044 among
all PHF6 summitswere selected and run inmotif discovery in par-
allel. Amotif length of eight was used and selected the top 10 sig-
nificant motifs returned by MEME (Bailey and Elkan 1994). The
motifs thus discovered were then tested for similarity to known
motifs (as in the JASPAR CORE 2014 vertebrates [Mathelier
et al. 2013], UniProbemouse [Hume et al. 2015], and other human
and mouse motifs [Jolma et al. 2013]) using the Tomtom tool
(Gupta et al. 2007) with a minimum motif overlap of one and
Pearson distance as the distance metric for motif similarity. To
identify other transcription factors that cobind with PHF6,
mm9 sequences were obtained for ±1-kb regions around the
TSSs of differentially expressed genes and tested for known
motif enrichment using the Bioconductor PWMEnrich package
(https://bioconductor.org/packages/release/bioc/html/PWMEnri
ch.html). A default Mus musculus genomic background and the
MotifDb database ofmotifs (https://rdrr.io/bioc/MotifDb) includ-
ed in the package were used, and a P-value threshold of 0.01 was
set for reporting significant transcription factors whose motifs
were enriched in the selected regions. Input sequences were ran-
domly shuffled 100 times, motif enrichment was performed for
each shuffled sequence set, andmotifs that came up as significant
(P < 0.001) in >5% of the shuffled sets were considered to be false
positive enrichments. A total of 28 motifs corresponding to 24
unique transcription factors passed the filtering step and were re-
ported as potential cobinding partners of PHF6 at the promoters
of differentially expressed genes (Supplemental Table 3). Gene
functionswere determined by using the PANTHER classification
system (Thomas et al. 2003; Mi et al. 2004).
ChIP-qPCR
ChIP was performed as above. qPCR reactions were performed
as described above. Quantities were normalized to input,
calculated using the ΔΔCT method, and expressed as fold enrich-
ment relative to a negative binding control (Pchd10). The primer
sequences (forward/reverse) used were Btg2 (5′-GACACTGACA-
GAGCCGTTCA-3′; 5′ACACTCCTCCCACCAAACAG-3′),
Cd74 (5′-GATGGCTACTCCCTTGCTGA-3′; 5′-GATGGC-
TACTCCCTTGCTGA-3′), Cd4 (5′-TCTCCTGCTTCAGGGT-
CAGT-3′; 5′-AGGGACACCCTGTTTCTGTG-3′), Gata3 (5′-
AGCCCAGGACTGACTAAGCA-3′; 5′-TGTTTGGGGGTTT
GTTTGTT-3′), and Pchd10 (5′-CCCTGGACTTGCTGACT
AGC-3′; 5′-GTGCAAACCAGAACATGGTG-3′).
Chromatin accessibility by ATAC-seq
ATAC-seq libraries from Phf6WT and Phf6KO B-ALL cells were
constructed as reported previously (Buenrostro et al. 2013). For
the ATAC-seq data analysis, mapped ATAC reads were summa-
rized into 500-bp bins. The DESeq2 package in R (Love et al.
2014) was then applied to the binned reads to analyze for differen-
tial chromatin accessibility between Phf6 wild-type and knock-
out cells. To call differentially accessible chromatin regions, we
used a fold change cutoff of >2 and a FDRcutoff of <0.001.GREAT
(genomic regions of enrichment annotations tool) (McLean et al.
2010) was used to analyze for enriched gene sets and other geno-
mic features in the regions that were more or less accessible in
Phf6KO cells separately. To test enrichment of known and de
novo sequencemotifs within these differentially accessible chro-
matin regions, we used theHOMERmotif analysis toolkit (Heinz
et al. 2010) on these regions using all mappable ATAC regions as
background and the UCSCmm9 genome, with all other parame-
ters set to default values.
NucleoATAC software was used with default parameters to
call nucleosome signals from raw ATAC-seq signals in Phf6WT
cells (Schep et al. 2015, 2017). Background-corrected nucleosome
signals ±1 kb fromTSSs annotated in themm9 genomewere then
stacked into a heat map with rows corresponding to individual
TSSs ordered by gene expression in Phf6WT cells. To visualize
PHF6 occupancy at these sites, a heat map of normalized PHF6
signals in the same row order was also generated. ATAC-seq
raw data and processed TSS nucleosome signals are available in
the GEO database with accession number GSE98716 under
superseries GSE77457.
Statistical analysis
Results are expressed as means ± standard deviation. If not stated
otherwise, statistical significance was determined with Prism
software (GraphPad version 6.0) by comparison of mean values
by the two-tailed unpaired Student’s t-test on two experimental
conditions, with P < 0.05 considered statistically significant.
Statistical significance levels are designated as follows: P < 0.05
(∗), P < 0.01 (∗∗), P < 0.001 (∗∗∗), P < 0.0001 (∗∗∗∗), and not significant
(n.s.). Survival curves were generated using Prism software
(GraphPad version 6.0), and the Mantel-Cox test was applied to
pairwise comparisons of survival data. No statistical methods
were used to predetermine sample size.
Accession numbers
All RNA-seq and ChIP-seq data sets have been deposited into the
NCBIGEO repository under BioProjectIDGSE74878. TheATAC-
seq data set and processed TSS nucleosome signals are available
in the GEO database with accession number GSE98716 under
superseries GSE77457.
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